

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 9, 2018

OptimizeRx Corporation

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction  
of incorporation)

000-53605

(Commission File Number)

26-1265381

(I.R.S. Employer  
Identification No.)

400 Water Street, Suite 200, Rochester, MI

(Address of principal executive offices)

48307

(Zip Code)

Registrant's telephone number, including area code: 248.651.6568

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## **SECTION 8 – Other Events**

### **Item 8.01 Other Events**

On January 9, 2018, we issued a press release announcing an expanded partnership with Allscripts Healthcare. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

## **SECTION 9 – Financial Statements and Exhibits**

### **Item 9.01 Financial Statements and Exhibits**

99.1 [Press release, dated January 9, 2018](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**OptimizeRx Corporation**

/s/ Douglas Baker

Douglas Baker  
Chief Financial Officer

Date: January 10, 2018



**OptimizeRx Expands Exclusive Partnership with Allscripts for Prescription Cost Savings and Real-time Messaging at Point-of-Care**

**Rochester, MI (January 9, 2018)** — OptimizeRx Corp. (OTCQB: OPRX), the nation’s leading provider of digital health messaging, has expanded its partnership with Allscripts Healthcare (NASDAQ:MDRX) which now includes a variety of real-time messaging to Allscripts ambulatory platforms. The agreement includes financial, informational, and clinical messaging delivered at the point-of-care through Allscripts ePrescribe™, Allscripts Professional EHR™ and Allscripts TouchWorks® EHR solutions.

“Our goal at OptimizeRx is to help make medications more affordable, encourage greater adherence, and provide important clinical information,” commented Miriam Paramore, president of OptimizeRx. “Supported by our pharma partners, OptimizeRx and Allscripts continue to empower healthcare providers to make better decisions and deliver better, more affordable care for healthier patients, populations and communities.”

Allscripts’ industry leading electronic health record (EHR) and ePrescribing (eRx) network totals more than 180,000 physicians across 45,000 ambulatory facilities, 2,500 hospitals and 17,000 post-acute organizations. In 2017, Allscripts achieved an industry-leading milestone of one billion data exchange transactions through its platform – the most in a single year.

OptimizeRx’s growing EHR and eRx network now reaches more than 500,000 healthcare providers (HCPs) in the U.S., making it the healthcare industry’s largest point-of-prescribe network. It delivers real-time access to financial assistance, education, and critical clinical information from pharma companies to HCPs.

“Our long-running relationship with Allscripts, a recognized global leader in healthcare information technology, reflects the unmatched value proposition we offer to our EHR and pharma manufacturer partners,” said William Febbo, CEO of OptimizeRx. “Allscripts’ continued innovation around real-time messaging on its network helps sets the stage for stronger revenue growth and pharma partner relationships in the New Year.”

**About OptimizeRx**

OptimizeRx® (OTCQB: OPRX) is the nation's leading provider of digital health messaging via electronic health records (EHRs), providing a direct channel for pharma companies to communicate with healthcare providers. The company's cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information. The company's network is comprised of leading EHR platforms like Allscripts, Amazing Charts and Quest, and provides more than half a million healthcare providers access to these benefits within their workflow at the point of care. For more information, follow the company on [Twitter](#), [LinkedIn](#) or visit [www.optimizerx.com](http://www.optimizerx.com).

**Important Cautions Regarding Forward Looking Statements**

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

**OptimizeRx Contact:**

Doug Baker, CFO  
Tel (248) 651-6568 x807  
dbaker@optimizerx.com

**OptimizeRx Investor Relations:**

Ron Both, CMA  
Tel (949) 432-7557  
opr@cma.team